Physician profile
Enedelia Barrera
NPI 1508941683
$6,653.44
in general payments reported to CMS, 2019-2025
16 companies · $498 in 2025
The $498 reported for 2025 was more than what 77% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,635 · 2020: $679 · 2021: $1,050 · 2022: $785 · 2023: $1,251 · 2024: $755 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,503.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $4,413.85 | 2019-2025 | Total30, Precision 1, Dailies Total1 |
| Dompe US, INC. | $402.17 | 2023-2025 | Oxervate |
| Coopervision INC. | $308.19 | 2020-2023 | Biofinity Contact Lens |
| Allergan, INC. | $229.37 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $198.81 | 2023-2024 | Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $190.40 | 2019 | |
| Lkc Technologies, INC. | $137.05 | 2024 | |
| Novartis Pharmaceuticals Corporation | $127.89 | 2019-2020 | |
| Biotissue Holdings INC. | $115.61 | 2023 | |
| Aerie Pharmaceuticals, INC. | $110.40 | 2019 | |
| Rxsight INC | $103.41 | 2022 | |
| Maculogix, INC. | $102.85 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $97.33 | 2025 | |
| Amgen INC. | $86.33 | 2024 | Tepezza |
| Carl Zeiss Meditec Ag | $17.20 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Enedelia Barrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.